Non-randomized, prospective, non-controlled study of changes of lipid parameters after introduction of evolocumab in patients with heterozygous familial hypercholesterolemia under LDL-apheresis therapy.
Phase of Trial: Phase II
Latest Information Update: 13 Dec 2016
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- 08 Dec 2016 Status changed from recruiting to completed.
- 22 Jun 2016 New trial record